NewAmsterdam Pharma Co N.V. (NAMS) Institutional Ownership

Ownership Summary

NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS) has 165 institutional investors that have filed 13F reports for the period ending March 2026.

• These investors held 857.4% of outstanding shares in March 2026, up from 837.6% in December 2025.
• They increased total shares held in NAMS by 5.41% quarter over quarter, and investors in NewAmsterdam Pharma increased 27.91% from a year ago.
• Activity in NAMS broke down as 92 buyers, 47 sellers, and 26 unchanged among 165 total holders.
• Institutional investors collectively held 125.13Mn shares in NewAmsterdam Pharma as of March 2026, up by 6.43Mn shares quarter on quarter, and up 10.76Mn shares year over year.
• Frazier Life Sciences Management, L.P. leads ownership in NAMS with 16.94Mn shares as of March 31, 2026, equal to 116.1% of outstanding shares.
• Top purchasers of NAMS stock for the quarter ending March 2026 included FMR LLC (2.35Mn), WESTFIELD CAPITAL MANAGEMENT CO LP (2.2Mn), Janus Henderson Group Plc (2.18Mn), Capital World Investors (1.13Mn), BNP Paribas Asset Management Holding S.A. (780.43K).
• The largest sales of NAMS for the quarter ending March 2026 came from Goldman Sachs Group Inc (1.5Mn), Pictet Asset Management Holding SA (739.59K), JENNISON ASSOCIATES LLC (738.82K), Capital International Investors (621.4K), First Turn Management, LLC (335.14K).
• Per Business Quant, the top 10 investors in NAMS for the quarter ending March 2026 include Frazier Life Sciences Management, L.P. (16.94Mn), Capital World Investors (11.11Mn), RA CAPITAL MANAGEMENT, L.P. (9.55Mn), FCPM III SERVICES B.V. (9.2Mn), FMR LLC (8.77Mn), Bain Capital Life Sciences Investors, LLC (7.31Mn), WELLINGTON MANAGEMENT GROUP LLP (5.12Mn), Janus Henderson Group Plc (4.52Mn), DEERFIELD MANAGEMENT COMPANY, L.P. (4.26Mn), VIKING GLOBAL INVESTORS LP (4.2Mn).